The ongoing phase 2 basket study SGNTUC-019 (NCT04579380) is evaluating tucatinib, a HER2 inhibitor approved for breast cancer and CRC, in combination with trastuzumab in patients with metastatic HER2-altered solid tumors. This evidence concerns the gene ERBB2 and colorectal carcinoma.